Tinzaparin for the prevention of thromboembolic events in ambulatory patients with metastatic colorectal cancer receiving first line treatment: a randomised, clinical trial design.

Colorectal cancer (CRC) is the third most commonly diagnosed cancer worldwide. CRC leads to increased activation of the clotting system. Since CRC patients present a higher rate of bleeding, careful evaluation of the risk/benefits of anticoagulant prophylaxis is necessary.

Detalhes bibliográficos
Autores: Salgado M, de la Camara-Gómez J, García-Escobar I, Álvarez-Llosa RC, González-Villarroel P, Garay DF, Pàmpols-Felip M, Guillot-Morales M, Pelegrín-Mateo FJ, Jimenez-Orozco E, Sastre J, de Castro EM, Coma E, Bouzas LP, Ferrer-Pérez AI, Mompradé-Olivé E, Cousillas-Castiñeiras A, Covela-Rúa M, Rojas M, Querol R, Díaz LR, Merino M, Gil M, Sánchez-Cánovas M, Elías T, Marrupe-González D, Sánchez-Gil B, Carmona-Campos M, García-Ferrón M, Soria JM, Muñoz A
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2025
País:España
Recursos:Institut d'Investigació i Innovació Parc Taulí (I3PT)
Repositorio:r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
OAI Identifier:oai:i3pt.fundanetsuite.com:p6834
Acesso em linha:https://i3pt.portalinvestigacion.com/publicaciones/6834
https://www.scopus.com/inward/record.uri?eid=2-s2.0-105022125501&doi=10.1186%2Fs12885-025-14620-z&partnerID=40&md5=787efbd1186194223962727c327170e2
Access Level:acceso abierto
Palavra-chave:Colorectal cancer, Genetics, Metastatic, Risk factors, Thromboprophylaxis, Venous thromboembolism
Descrição
Resumo:Colorectal cancer (CRC) is the third most commonly diagnosed cancer worldwide. CRC leads to increased activation of the clotting system. Since CRC patients present a higher rate of bleeding, careful evaluation of the risk/benefits of anticoagulant prophylaxis is necessary.

Registos relacionados